https://pepsreview.com/articles/thailand-makes-glp-1-injections-prescription-only PepsReview en 2026-09-15 Thailand GLP-1 prescription, semaglutide regulation, weight-loss injection pens, Thai FDA, counterfeit peptides, GLP-1 enforcement, prescription-only https://pepsreview.com/articles/counterfeit-semaglutide-peptide-hospitalizes-new-zealand-user PepsReview en 2026-09-15 counterfeit semaglutide, peptide safety, unregulated injectables, GLP-1 counterfeit, independent testing, certificate of analysis, peptide verification https://pepsreview.com/articles/novo-nordisk-rebrands-as-novo-glp-1-strategic-reset PepsReview en 2026-09-15 Novo Nordisk rebrand, Novo, GLP-1 market, Wegovy, Ozempic, Zepbound competition, semaglutide, peptide safety https://pepsreview.com/articles/fda-glp-1-green-list-faces-shutdown-call-over-counterfeit-api-risk PepsReview en 2026-09-14 GLP-1, FDA Green List, counterfeit semaglutide, API imports, peptide testing, tirzepatide, supply chain, Import Alert 66-80 https://pepsreview.com/articles/saxenda-users-join-naion-litigation-vision-loss-claims-expand-liraglutide PepsReview en 2026-09-14 Saxenda lawsuit, liraglutide NAION, GLP-1 litigation, vision loss, Novo Nordisk, NAION claims, incretin safety, drug safety news https://pepsreview.com/articles/australian-patient-torn-oesophagus-unapproved-peptide PepsReview en 2026-09-14 peptide safety Australia, unapproved peptide, torn oesophagus, TGA warning, gray market peptides, peptide injury, research peptide testing https://pepsreview.com/articles/zepbound-lawsuits-2026-who-qualifies-file-claim PepsReview en 2026-09-14 Zepbound lawsuit, GLP-1 litigation, tirzepatide lawsuit, Eli Lilly, gastroparesis lawsuit, GLP-1 MDL, who qualifies, drug injury claim